Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000301

Drug Information
NameFlutamide
SynonymsZINC03812944; LS-2105; Prestwick2_000180; MLS000069634; UNII-76W6J0943E; CHEBI:5132; Oncosal; Flutamin; BSPBio_003122; Alphapharm Brand of Flutamide; KBioGR_001377; Spectrum_001210; Tedec Meiji Brand of Flutamide; NCGC00091460-08; Prostandril; SPBio_000982; KBio2_004258; NCGC00091460-04; Prostogenat; Prasfarma Brand of Flutamide; Gry Brand of Flutamide; C07653; Prestwick3_000180; CID3397; Juta Brand of Flutamide; Apotex Brand of Flutamide; Flumid; Schering-Plough Brand of Flutamide; Ipsen Brand of Flutamide; CCRIS 7246; Q-Pharm Brand of Flutamide; 37209-54-4; m-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-; KBioSS_001690; Testotard; Spectrum3_001421; Eulexin; PMS-Flutamide; Fluta GRY; Prestwick0_000180; SAM002264612; Fluta 1A Pharma; m-Propionotoluidide, .alpha.,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-; cell pharm Brand of Flutamide; NSC215876; PMS Flutamide; FlutaGRY; CPD000058187; m-Propionotoluidide, 2-methyl-4'-nitro-alpha,alpha,alpha-triflouro-; Flutamidum; 4'-Nitro-3'-trifluoromethylisobutyranilide; niftolid; Flutamide (pubertal study); DB00499; ST058409; Prostica; D005485; F 9397; Prestwick_228; Propanamide, 2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-; Drogenil; Flulem; flutamide; Cebatrol; Flutacell; Flutaplex; BRN 2157663; Prestwick1_000180; NCGC00091460-05; Schering Brand of Flutamide; NCGC00091460-01; Niftholide; Novo-Flutamide; AC1L1FUE; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; METHOXYCHLOR; ETHINYL ESTRADIOL); HMS1568D21; IDI1_000459; BPBio1_000087; Flutamide USP25; Sch 13521; Flutamide [USAN:BAN:INN]; EINECS 236-341-9; NSC 215876; m-Propionotoluidide, 2-methyl-4'-nitro-.alpha.,.alpha.,.alpha.-trifluoro-; Flutamide (JAN/USP/INN); Fugerel; KBio3_002342; NCGC00091460-09; TAD Brand of Flutamide; Prostacur; 4-Nitro-3-(trifluoromethyl)isobutyranilide; KBio2_006826; AKOS001025465; NCGC00015452-02; 337962-98-8; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; BRD-K28307902-001-05-0; Flutamidum [INN-Latin]; Chephasaar Brand of Flutamide; Lemery Brand of Flutamide; NCGC00015452-04; NSC147834; Spectrum2_001201; Essex Brand of Flutamide; F9397_SIGMA; NCGC00091460-02; NCGC00015452-12; I01-2470; HMS2090I18; esparma Brand of Flutamide; NCGC00015452-01; MLS001065596; F0663; Chiron Brand of Flutamide; 4'-Nitro-3'-trifluoromethylisobutyramilide; NovoFlutamide; Eulexine; 13311-84-7; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; KBio2_001690; Flutamida; KBio1_000459; Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-; Apimid; Odyne; Fluken; Lopac-F-9397; HMS2092O14; alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; Ham's F-12 medium; Sch-13521; ApoFlutamide; Kendrick Brand of Flutamide; SPECTRUM1500995; m-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; Chimax; Lopac0_000557; Hexal Brand of Flutamide; MolPort-001-771-894; EU-0100557; SPBio_002000; Pharmascience Brand of Flutamide; Flutexin; m-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro- (8CI); Schering Plough Brand of Flutamide; AB00052188; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; Ciclum Brand of Flutamide; Azupharma Brand of Flutamide; Eulexin (TN); NCGC00091460-06; CHEMBL806; Cytamid; CAS-13311-84-7; Novo Flutamide; Flutandrona; Spectrum5_001450; BSPBio_000079; NCGC00091460-03; NCGC00091460-07; .alpha.,.alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; Niftolide; NFBA; AC-10517; Apogepha Brand of Flutamide; SCH13521; DivK1c_000459; 1A Brand of Flutamide; Spectrum4_000829; Apo-Flutamide; SMR000058187; Fluta cell; C11H11F3N2O3; Fluta-cell; Cebatrol, veterinary; S1908_Selleck; Flutamida [INN-Spanish]; HMS1921O16; Q Pharm Brand of Flutamide; NK-601; Inibsa Brand of Flutamide; NINDS_000459; D00586; Fluta-GRY; HMS501G21; Eulexin, Flutamin, Drogenil,Flutamide; Novopharm Brand of Flutamide; Apo Flutamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
Trade NameEulexin
CompanySchering-Plough Corporation
IndicationProstate CancerApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)1
4/h3-6H,1-2H3,(H,15,17)
InChIKeyMKXKFYHWDHIYRV-UHFFFAOYSA-N
Canonical SMILESCC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 13311-84-7
FormulaC11H11F3N2O3
PubChem Compound IDCID 3397.
PubChem Substance IDSID 9855.
ChEBI5132;
SuperDrug ATC IDL02BB01
SuperDrug CAS ID013311847;
TargetAndrogen receptorAntagonist[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075298 To Reference
Ref 2Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543